EP 1261708 A2 20021204 - COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF PROSTATE CANCER
Title (en)
COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF PROSTATE CANCER
Title (de)
ZUSAMMENSETZUNGEN UND VERFAHREN ZUR BEHANDLUNG UND DIAGNOSE VON PROSTATKREBS
Title (fr)
COMPOSITIONS ET METHODES DESTINEES AU TRAITEMENT ET AU DIAGNOSTIQUE DU CANCER DE LA PROSTATE
Publication
Application
Priority
- US 0101574 W 20010116
- US 48367200 A 20000114
Abstract (en)
[origin: WO0151633A2] Compositions and methods for the therapy and diagnosis of cancer, particularly prostate cancer, are disclosed. Illustrative compositions comprise one or more prostate-specific polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly prostate cancer.
IPC 1-7
IPC 8 full level
G01N 33/574 (2006.01); A61K 31/7088 (2006.01); A61K 38/00 (2006.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61P 35/00 (2006.01); A61P 37/04 (2006.01); C07K 14/11 (2006.01); C07K 14/47 (2006.01); C07K 16/18 (2006.01); C07K 19/00 (2006.01); C12N 1/15 (2006.01); C12N 1/19 (2006.01); C12N 1/21 (2006.01); C12N 5/08 (2006.01); C12N 5/10 (2006.01); C12N 9/64 (2006.01); C12N 15/09 (2006.01); C12N 15/12 (2006.01); C12Q 1/02 (2006.01); C12Q 1/68 (2006.01)
CPC (source: EP KR US)
A61K 39/4611 (2023.05 - EP KR US); A61K 39/4632 (2023.05 - EP KR US); A61K 39/464494 (2023.05 - EP KR US); A61P 35/00 (2018.01 - EP); A61P 37/04 (2018.01 - EP); C07K 14/005 (2013.01 - EP); C12N 9/6424 (2013.01 - EP); C12N 15/11 (2013.01 - KR); A61K 39/00 (2013.01 - EP KR US); A61K 2039/53 (2013.01 - EP); C07K 2319/00 (2013.01 - EP); C12N 2760/16022 (2013.01 - EP)
Citation (examination)
- STUBBS A. ET AL: "Differentially expressed genes in hormone refractory prostate cancer", AMERICAN JOURNAL OF PATHOLOGY, vol. 154, no. 4, May 1999 (1999-05-01), US, pages 1335 - 1343
- GIRI D. ET AL: "Alterations in the expression of basic Fibroblast Growth Factor (FGF) 2 and its receptor FGFR-1 in human prostate cancer", CLINICAL CANCER RESEARCH, vol. 5, no. 5, May 1999 (1999-05-01), US, pages 1063 - 1071
Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR
DOCDB simple family (publication)
WO 0151633 A2 20010719; WO 0151633 A3 20020620; WO 0151633 A9 20021031; AU 3447401 A 20010724; BR 0107643 A 20030610; CA 2397741 A1 20010719; CN 1436234 A 20030813; CZ 20022756 A3 20030212; EP 1261708 A2 20021204; HU P0203968 A2 20030328; HU P0203968 A3 20040928; IL 150732 A0 20030212; JP 2003528591 A 20030930; KR 20030016217 A 20030226; MX PA02006934 A 20030128; NO 20023402 D0 20020715; NO 20023402 L 20020829; PL 356908 A1 20040712; RU 2002121771 A 20040310; ZA 200206400 B 20040121
DOCDB simple family (application)
US 0101574 W 20010116; AU 3447401 A 20010116; BR 0107643 A 20010116; CA 2397741 A 20010116; CN 01806526 A 20010116; CZ 20022756 A 20010116; EP 01906582 A 20010116; HU P0203968 A 20010116; IL 15073201 A 20010116; JP 2001551207 A 20010116; KR 20027009144 A 20020715; MX PA02006934 A 20010116; NO 20023402 A 20020715; PL 35690801 A 20010116; RU 2002121771 A 20010116; ZA 200206400 A 20020812